Molecular Imaging of Renal Cell Carcinoma

Urologic Clinics of North America

Volumn 35, Issue 4, 2008, Pages 605-611

  Perini, Rodolfo ^a   Pryma, Daniel ^a   Divgi, Chaitanya ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cancer phenotype; Molecular imaging; PET

Indexed keywords

ACETIC ACID; ACETYL COENZYME A; ANTIBODY; CARBON 11; CG250; CG250 I 124; CHOLINE; FLUORODEOXYGLUCOSE F 18; GLUCOSE; INDIUM 111; IODINE; IODINE 124; IODINE 131; IODINE DERIVATIVE; KI 67 ANTIGEN; RADIOACTIVE MATERIAL; THYMIDINE; TRACER; UNCLASSIFIED DRUG;

CLEAR CELL CARCINOMA; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; GLUCOSE METABOLISM; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOIMMUNOASSAY; REVIEW; TUMOR DIFFERENTIATION; TUMOR VOLUME; ULTRASOUND;

ACETATES; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CARBON; CARCINOMA, RENAL CELL; FLUORODEOXYGLUCOSE F18; GENETIC MARKERS; HUMANS; IODINE RADIOISOTOPES; KIDNEY NEOPLASMS; MOLECULAR PROBE TECHNIQUES; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS;

EID: 55049104308     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2008.07.015     Document Type: Review

References (40)

1. Israel G.M., and Bosniak M.A. How I do it: evaluating renal masses. Radiology 236 2 (2005) 441-450
2. Bosniak M.A., and Rofsky N.M. Problems in the detection and characterization of small renal masses. Radiology 198 3 (1996) 638-641
3. Raj G.V., Thompson R.H., Leibovich B.C., et al. Preoperative nomogram predicting 12-year probability of metastatic renal cancer. J Urol 179 6 (2008) 2146-2151 [discussion 2151]
4. Raj G.V., Bach A.M., Iasonos A., et al. Predicting the histology of renal masses using preoperative Doppler ultrasonography. J Urol 177 1 (2007) 53-58
5. Zhang J., Tehrani Y.M., Wang L., et al. Renal masses: characterization with diffusion-weighted MR imaging-a preliminary experience. Radiology 247 2 (2008) 458-464
6. Zhang J., Lefkowitz R.A., Ishill N.M., et al. Solid renal cortical tumors: differentiation with CT. Radiology 244 2 (2007) 494-504
7. Prasad S.R., Dalrymple N.C., and Surabhi V.R. Cross-sectional imaging evaluation of renal masses. Radiol Clin North Am 46 1 (2008) 95-111 vi-vii
8. Warburg O., Posener K., and Negelein E. Ueber den Stoffwechsel der Tumoren. Biochem Z 152 (1924) 319-344
9. Kim J.W., and Dang C.V. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 66 18 (2006) 8927-8930
10. Hevesy G. Some applications of isotopic indicators. Les Prix Nobel en 1940-44 (1946), Norstedt & Soener, Stockholm (Sweden)
11. Weber W.A., Schwaiger M., and Avril N. Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl Med Biol 27 7 (2000) 683-687
12. Juweid M.E., and Cheson B.D. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 354 5 (2006) 496-507
13. Juweid M.E., Stroobants S., Hoekstra O.S., et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25 5 (2007) 571-578
14. Bouchelouche K., and Oehr P. Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review. J Urol 179 1 (2008) 34-45
15. Powles T., Murray I., Brock C., et al. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol 51 6 (2007) 1511-1520 [discussion 1520-1]
16. Bachor R., Kotzerke J., Gottfried H.W., et al. [Positron emission tomography in diagnosis of renal cell carcinoma]. [German]. Der Urologe Ausg A 35 2 (1996) 146-150
17. Goldberg M.A., Mayo-Smith W.W., Papanicolaou N., et al. FDG PET characterization of renal masses: preliminary experience. Clin Radiol 52 7 (1997) 510-515
18. Aide N., Cappele O., Bottet P., et al. Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging 30 9 (2003) 1236-1245
19. Kang D.E., White R.L., Zuger J.H., et al. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol 171 5 (2004) 1806-1809
20. Ramdave S., Thomas G.W., Berlangieri S.U., et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 166 3 (2001) 825-830
21. Choi Y., Huang S.C., Hawkins R.A., et al. A refined method for quantification of myocardial oxygen consumption rate using mean transit time with carbon-11-acetate and dynamic PET. J Nucl Med 34 11 (1993) 2038-2043
22. Juillard L., Lemoine S., Janier M.F., et al. Validation of renal oxidative metabolism measurement by positron-emission tomography. Hypertension 50 1 (2007) 242-247
23. Soloviev D., Fini A., Chierichetti F., et al. PET imaging with (11)C-acetate in prostate cancer: a biochemical, radiochemical and clinical perspective. Eur J Nucl Med Mol Imaging 35 5 (2008) 942-949
24. Shriki J., Murthy V., and Brown J. Renal oncocytoma on 1-11C acetate positron emission tomography: case report and literature review. Mol Imaging Biol 8 4 (2006) 208-211
25. Kotzerke J., Linné C., Meinhardt M., et al. [1-(11)C]acetate uptake is not increased in renal cell carcinoma. Eur J Nucl Med Mol Imaging 34 6 (2007) 884-888
26. Shields A.F. Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology. Mol Imaging Biol 8 3 (2006) 141-150
27. Buck A.K., Bommer M., Stilgenbauer S., et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res 66 22 (2006) 11055-11061
28. Takahashi N., Inoue T., Lee J., et al. The roles of PET and PET/CT in the diagnosis and management of prostate cancer. Oncology 72 3-4 (2007) 226-233
29. Glunde K., Jacobs M.A., and Bhujwalla Z.M. Choline metabolism in cancer: implications for diagnosis and therapy. Expert Rev Mol Diagn 6 6 (2006) 821-829
30. Skinnider B.F., and Amin M.B. An immunohistochemical approach to the differential diagnosis of renal tumors. Semin Diagn Pathol 22 1 (2005) 51-68
31. Carlson R.W., Moench S.J., Hammond M.E., et al. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 4 Suppl 3 (2006) S1-S22 [quiz S23-4]
32. Lawrentschuk N., Davis I.D., Bolton D.M., et al. Positron emission tomography (PET), immuno-PET and radioimmunotherapy in renal cell carcinoma: a developing diagnostic and therapeutic relationship. BJU Int 97 5 (2006) 916-922
33. Capromab pendetide: product approval iInformation - licensing action. Available at:. http://www.fda.gov/cder/biologics/products/capcyt102896.htm Accessed May 18, 2008
34. Iodine-124. Available at:. http://en.wikipedia.org/wiki/Iodine-124 Accessed May 18, 2008
35. Oosterwijk E., Divgi C., and Bander N.H. Active and passive immunotherapy: vaccines and antibodies. BJU Int 99 5 Pt B (2007) 1301-1304
36. Oosterwijk E., Divgi C.R., Brouwers A., et al. Monoclonal antibody-based therapy for renal cell carcinoma. Urol Clin North Am 30 3 (2003) 623-631
37. Divgi C.R., O'Donoghue J.A., Welt S., et al. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med 45 8 (2004) 1412-1421
38. Huang W.C., Kagiwada M.A., and Russo P. Surgery insight: advances in techniques for open partial nephrectomy. Nat Clin Pract Urol 4 8 (2007) 444-450
39. Sorbellini M., Kattan M.W., Snyder M.E., et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 173 1 (2005) 48-51
40. Divgi C.R., Pandit-Taskar N., Jungbluth A.A., et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 8 4 (2007) 304-310